

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

PATENT SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
Angiotech Florida Holdings, Inc.	06/08/2010

RECEIVING PARTY DATA

Name:	Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as agent
Street Address:	2450 Colorado Avenue
Internal Address:	Suite 3000
City:	Santa Monica
State/Country:	CALIFORNIA
Postal Code:	90404

PROPERTY NUMBERS Total: 10

Property Type	Number
Application Number:	07919252
Application Number:	08186590
Application Number:	08021302
Application Number:	08021212
Application Number:	08309583
Application Number:	08721434
Application Number:	08960660
Application Number:	10336936
Application Number:	09554745
Application Number:	10333169

CORRESPONDENCE DATA

Fax Number: (212)593-5955

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-756-2552

501206361

PATENT
REEL: 024546 FRAME: 0524

CH \$400.00 07919252

Email: marisa.davidson@srz.com
Correspondent Name: M. Davidson c/o Schulte Roth & Zabel LLP
Address Line 1: 919 Third Avenue
Address Line 2: 22nd Floor
Address Line 4: New York, NEW YORK 10022

ATTORNEY DOCKET NUMBER:

025983-0159

NAME OF SUBMITTER:

Marisa Davidson (025983-0159)

Total Attachments: 15

source=Angiotech Florida Patent Security Agreement#page1.tif
source=Angiotech Florida Patent Security Agreement#page2.tif
source=Angiotech Florida Patent Security Agreement#page3.tif
source=Angiotech Florida Patent Security Agreement#page4.tif
source=Angiotech Florida Patent Security Agreement#page5.tif
source=Angiotech Florida Patent Security Agreement#page6.tif
source=Angiotech Florida Patent Security Agreement#page7.tif
source=Angiotech Florida Patent Security Agreement#page8.tif
source=Angiotech Florida Patent Security Agreement#page9.tif
source=Angiotech Florida Patent Security Agreement#page10.tif
source=Angiotech Florida Patent Security Agreement#page11.tif
source=Angiotech Florida Patent Security Agreement#page12.tif
source=Angiotech Florida Patent Security Agreement#page13.tif
source=Angiotech Florida Patent Security Agreement#page14.tif
source=Angiotech Florida Patent Security Agreement#page15.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made this 8th day of June, 2010, among the Grantors listed on the signature pages hereof (collectively, "Grantors" and each individually "Grantor"), and WELLS FARGO CAPITAL FINANCE, LLC (f/k/a Wells Fargo Foothill, LLC), in its capacity as administrative agent for the Lender Group and the Bank Product Providers (together with its successors, "Agent").

WITNESSETH:

WHEREAS, pursuant to that certain Credit Agreement, dated as of February 27, 2009 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), among Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of the Province of British Columbia, Canada, as parent ("Parent"), each Subsidiary of Parent listed on the signature pages thereto as a "Borrower" (each a "Borrower" and collectively, "Borrowers"), the lenders party thereto as "Lenders" ("Lenders"), and Agent, the Lender Group is willing to make certain financial accommodations available to Borrowers pursuant to the terms and conditions thereof; and

WHEREAS, the members of Lender Group are willing to make the financial accommodations to Borrowers as provided for in the Credit Agreement, but only upon the condition, among others, that the Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group and the Bank Product Providers, that certain Security Agreement of even date herewith (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender Group and the Bank Product Providers, this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement or the Credit Agreement.
2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Each Grantor hereby grants to Agent, for the benefit of the Lender Group and the Bank Product Providers, a continuing first priority security interest (subject to Permitted Liens) in all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral"):
 - (a) all of its Patents and Patent Intellectual Property Licenses to which it is a party, including those patents and applications and material Patent Intellectual Property Licenses under which Grantor is an exclusive licensee referred to on Schedule I hereto;
 - (b) all reissues, continuations or extensions of the foregoing; and
 - (c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent licensed under any Intellectual Property License.
3. SECURITY FOR OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of all the Secured Obligations, whether now existing or

arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Obligations and would be owed by Grantors, or any of them, to Agent, the Lender Group, the Bank Product Providers or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. SECURITY AGREEMENT. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Agent, for the benefit of the Lender Group and the Bank Product Providers, pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

5. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Patent Security Agreement shall automatically apply thereto. Grantors shall give prompt notice in writing to Agent with respect to any such new patent rights. Without limiting Grantors' obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Agreement by amending Schedule I to include any such new patent rights of Grantors. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument. In proving this Patent Security Agreement or any other Loan Document in any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures delivered by a party by facsimile transmission or by e-mail transmission shall be deemed an original signature hereto.

7. CONSTRUCTION. Unless the context of this Patent Security Agreement or any other Loan Document clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms "includes" and "including" are not limiting, and the term "or" has, except where otherwise indicated, the inclusive meaning represented by the phrase "and/or." The words "hereof," "herein," "hereby," "hereunder," and similar terms in this Patent Security Agreement or any other Loan Document refer to this Patent Security Agreement or such other Loan Document, as the case may be, as a whole and not to any particular provision of this Patent Security Agreement or such other Loan Document, as the case may be. Section, subsection, clause, schedule, and exhibit references herein are to this Patent Security Agreement unless otherwise specified. Any reference in this Patent Security Agreement or in any other Loan Document to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). Any reference herein or in any other Loan Document to the satisfaction or repayment in full of the Obligations shall mean the repayment in full in cash (or cash collateralization in accordance with the terms of the Credit Agreement) of all Obligations other than unasserted contingent indemnification Obligations and other than any Bank Product Obligations that, at such time, are allowed by the applicable Bank Product Providers to remain outstanding and that are not required by the provisions of the Credit Agreement to be repaid or cash collateralized. Any reference herein to any Person shall be construed to include such Person's successors and assigns. Any requirement of a writing contained herein or in any other Loan Document shall be satisfied by the transmission of a Record and any Record so transmitted shall constitute a representation and warranty as to the accuracy and completeness of the information contained therein.

[SIGNATURE PAGE FOLLOWS]

3107128823

11:23:33 a.m. 06-11-2010


2/3

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Grantors:

ANGIOTECH FLORIDA HOLDINGS, INC.,
a Florida corporation.

By:
Title:


Secretary

ACCEPTED AND ACKNOWLEDGED BY:

WELLS FARGO CAPITAL FINANCE, LLC, as Agent

By: _____
Name: _____
Title: _____

PATENT SECURITY AGREEMENT

IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.


Grantors:

ANGIOTECH FLORIDA HOLDINGS, INC.,
a Florida corporation.

By: _____
Title: _____

ACCEPTED AND ACKNOWLEDGED BY:

WELLS FARGO CAPITAL FINANCE, LLC, as Agent

By: 
Name: DENNIS S. Reisman
Title: V.P.

SCHEDULE I
PATENTS AND PATENT APPLICATIONS

Owner	Country	Inv Title	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Australia	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	61515/94	6784399	1-Apr-97
Angiotech Florida Holdings, Inc.	Australia	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	35151/95	711298	20-Jan-00
Angiotech Florida Holdings, Inc.	Australia	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	97316/98	759145	11-Jul-03
Angiotech Florida Holdings, Inc.	Austria	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Austria	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Austria	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05

PATENT SECURITY AGREEMENT

LA_LAN01:238460.1B

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Belgium	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Belgium	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Belgium	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCT'S	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Canada	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	2113660	2113660	16-May-00
Angiotech Florida Holdings, Inc.	Canada	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE MADE OF CONCENTRATED COAGULATION FACTORS BY ACIDIC PRECIPITATION	2113663	2113663	28-Jun-05
Angiotech Florida Holdings, Inc.	Canada	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	2307380		11-Jul-03
Angiotech Florida Holdings, Inc.	Canada	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	2308462	2308462	24-Feb-09

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Canada	SPRAY HEAD FOR APPLYING A MULTI-COMPONENT MIXTURE	2415834		
Angiotech Florida Holdings, Inc.	Denmark	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Denmark	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Denmark	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Europe	SPRAY HEAD FOR APPLYING MULTI-COMPONENT MIXTURE	1958991		
Angiotech Florida Holdings, Inc.	France	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	France	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	France	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A	98951133.2	1027371	21-Sep-05

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
		POOL OF HUMAN PLASMA			
Angiotech Florida Holdings, Inc.	France	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	98963761.6	1032367	12-Aug-09
Angiotech Florida Holdings, Inc.	Germany	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Germany	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Germany	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	India	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	1927CAL98	185759	23-Nov-91
Angiotech Florida Holdings, Inc.	Ireland	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Ireland	THERAPEUTIC GRADE THROMBIN	95931863.5	0782616	11-Jan-06

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
		PRODUCTION AND PRODUCTS			
Angiotech Florida Holdings, Inc.	Ireland	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Ireland	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	98963761.6	1032367	12-Aug-09
Angiotech Florida Holdings, Inc.	Israel	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	135812	135812	21-Dec-07
Angiotech Florida Holdings, Inc.	Italy	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Italy	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Italy	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21 Sep-05
Angiotech Florida Holdings, Inc.	Japan	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR	7-522035	3492694	14-Nov-03

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
		XIII AND FIBRONECTIN			
Angiotech Florida Holdings, Inc.	Japan	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	8-510483	3628703	17-Dec-04
Angiotech Florida Holdings, Inc.	Japan	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	2000-518981	4278861	19-Mar-09
Angiotech Florida Holdings, Inc.	Netherlands	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Netherlands	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Netherlands	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	New Zealand	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	504246	504246	7-Jan-03
Angiotech Florida Holdings, Inc.	Norway	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	19971104	323460	14-May-07

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Norway	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	20002293	323299	28-Apr-00
Angiotech Florida Holdings, Inc.	Norway	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	20002357	326601	19-Jan-09
Angiotech Florida Holdings, Inc.	Poland	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	340300	194589	28-Sep-07
Angiotech Florida Holdings, Inc.	Portugal	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Portugal	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Portugal	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Russia	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	97106349	2144081	21-Jun-99

PATENT SECURITY AGREEMENT

Owner	Country	Inv Title	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Russia	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	2000113224	2236237	20-Sep-04
Angiotech Florida Holdings, Inc.	Spain	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Spain	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-0
Angiotech Florida Holdings, Inc.	Spain	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Sweden	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Sweden	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Sweden	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05

PATENT SECURITY AGREEMENT

Owner	Country	Inv Title	App No.	Pat No.	Issue Dt.
Angiotech Florida Holdings, Inc.	Switzerland	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	Switzerland	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	Switzerland	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	Switzerland	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	98963761.6	1032367	12-Aug-09
Angiotech Florida Holdings, Inc.	United Kingdom	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE COMPRISING FIBRINOGEN, FACTOR XIII AND FIBRONECTIN	94908221.8	0748337	30-Jun-99
Angiotech Florida Holdings, Inc.	United Kingdom	THERAPEUTIC GRADE THROMBIN PRODUCTION AND PRODUCTS	95931863.5	0782616	11-Jan-06
Angiotech Florida Holdings, Inc.	United Kingdom	PROCESS FOR THE PRODUCTION OF HIGHLY VIRAL SAFE COMPONENTS FOR FORMING FIBRIN GLUE FROM A POOL OF HUMAN PLASMA	98951133.2	1027371	21-Sep-05
Angiotech Florida Holdings, Inc.	United Kingdom	FIBRIN SEALANTS FOR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	98963761.6	1032367	12-Aug-09
Angiotech Florida Holdings, Inc.	United States	BIOCOMPATIBLE SURGICAL	07/919252		

PATENT SECURITY AGREEMENT

Owner	Country	InvTitle	App No.	Pat No.	Issue Dt.
	of America	IMPLANT			
Angiotech Florida Holdings, Inc.	United States of America	BIOCOMPATIBLE SURGICAL IMPLANT	08/186590	5630842	20-May-97
Angiotech Florida Holdings, Inc.	United States of America	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE MADE OF CONCENTRATED COAGULATION FACTORS BY "SALTING-OUT"	08/021302	5395923	07-Mar-95
Angiotech Florida Holdings, Inc.	United States of America	PROCESS FOR THE OBTENTION OF A BIOLOGICAL ADHESIVE MADE OF CONCENTRATED COAGULATION FACTORS BY ACIDIC PRECIPITATION	08/021212	5290918	01-Mar-94
Angiotech Florida Holdings, Inc.	United States of America	THERAPEUTIC GRADE THROMBIN PRODUCED BY CHROMATOGRAPHY	08/309583	5506127	09-Apr-96
Angiotech Florida Holdings, Inc.	United States of America	ARTIFICIAL COLLAGEN	08/721434	5856308	05-Jan-99
Angiotech Florida Holdings, Inc.	United States of America	PROCESS FOR PRODUCING THROMBIN FROM PLASMA	08/960660	5981254	09-Nov-99
Angiotech Florida Holdings, Inc.	United States of America	FIBRIN SEALANTS OR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	10/336936	6699484	02-Mar-04
Angiotech Florida Holdings, Inc.	United States of America	FIBRIN SEALANTS OR ADHESIVES COMPRISING HYALURONIC ACID DERIVATIVE MATERIAL	09/554745	6503527	07-Jan-03
Angiotech Florida Holdings, Inc.	United States of America	SPRAY HEAD FOR APPLYING A MULTI-COMPONENT MIXTURE	10/333169		

PATENT SECURITY AGREEMENT